CIZ
NEUTRALCizzle Biotechnology Announces Notice of Annual General Meeting
The diagnostics developer has announced the notice of its Annual General Meeting, which will be held on 30 June 2025.
Cizzle Biotechnology Holdings
1.5000GBX
-3.23%
Market Cap
5.95M
Volume
2.45M
194% of avg
P/E Ratio
EPS (TTM)
Beta
0.7
Day Range
1.4200p - 1.5700p
52 Week Range
1.3000p1.5000p2.6850p
1.5000p
Upcoming Events
CIZ
NEUTRALCizzle Biotechnology Announces Holding(s) in Company
The biotechnology company has announced a change in its major shareholding structure.
CIZ
GOODCizzle Biotechnology Raises £150,000 Through Convertible Loan Note
The diagnostics developer has raised £150,000 through a convertible loan note to support the rollout of its early cancer test in the UK and Europe, following a licensing deal in North America.
CIZ
GOODCizzle Biotechnology Publishes 2024 Annual Results
The diagnostics developer publishes its annual results, providing limited details on its progress in developing an early lung cancer detection test.
CIZ
GOODCizzle Biotechnology Secures First Caribbean Contract for CIZ1B Biomarker Test
The diagnostics developer has secured its first contract in the Caribbean for its CIZ1B biomarker test, triggering early royalty payments and signaling progress in the commercialization of its technology.
CIZ
NEUTRALCizzle Biotechnology Launches New Corporate Website
The diagnostics developer has launched a new corporate website to provide information and updates to stakeholders.
CIZ
NEUTRALCizzle Biotechnology Appoints New Non-Executive Director
The healthcare company has appointed a new non-executive director to strengthen its strategic and business capabilities.
CIZ
NEUTRALCizzle Biotechnology Appoints First US Lab to Launch CIZ1B Cancer Test
The diagnostics developer has appointed a COLA accredited and CLIA certified lab in the US to launch its CIZ1B biomarker test for early-stage lung cancer detection.
CIZ
GOODCizzle Biotechnology Appoints New Chief Scientific Officer, Advances Lung Cancer Biomarker Assay
The diagnostics developer has appointed a new Chief Scientific Officer and made progress on its lung cancer biomarker assay, positioning the company for potential growth.
CIZ
GOODCizzle Biotechnology Expands North American Partnership to Include Caribbean
The diagnostics developer has expanded its North American partnership to include the Caribbean, securing early royalty payments and its first accredited laboratory partner as it advances towards product launch.